All posts by: Michael Zand

EAU 2018: Systemic Immunotherapy in Urological Cancers: Basics and Beyond – Monotherapy or Combinations for …
UroToday
The role of immunotherapy in bladder cancer continues to grow and currently is approved for the use in the second line setting and in the first line treatment in patient’s ineligible for platinum-based chemotherapy. As a second line agent immunotherapy …